{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:26Z","timestamp":1792601486443,"version":"4.5.0"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T00:00:00Z","timestamp":1171929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Peripheral T\u2010cell lymphomas (PTCLs) are a biologically heterogeneous subgroup of lymphomas with poor prognosis. In this study, the authors analyzed the clinical behaviors of PTCLs and diffuse large B\u2010cell lymphoma (DLBCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors compared the characteristics and outcomes of 59 patients with PTCLs, including 33 angioimmunoblastic T\u2010cell lymphomas and 26 unspecified peripheral T\u2010cell lymphomas, with the characteristics and outcomes of 193 patients with DLBCLs who were treated in the era before rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Based on the clinical characteristics, elevated lactate dehydrogenase (LDH), poor PS, advanced stage, higher International Prognostic Index score, and B symptoms were more common in patients with PTCLs, and bulky mass was more common in patients with DLBCL. The rates of complete response (CR) or an unconfirmed CR (CRu) were higher in patients with DLBCL (72%) than in patients with PTCLs (56%; <jats:italic>P<\/jats:italic> = .03). The 5\u2010year overall survival (OS), progression\u2010free survival (PFS), and disease\u2010free survival (DFS) rates were 31%, 26%, and 47%, respectively, in patients with PTCLs and 59%, 55%, and 73%, respectively, in patients with DLBCL (<jats:italic>P<\/jats:italic> = .001, <jats:italic>P<\/jats:italic> &lt; .001, and <jats:italic>P<\/jats:italic> = .003, respectively). Although multivariate analysis identified several risk factors that were significant in PTCLs, but not in DLBCLs, for the CR\/CRu, OS, PFS, and DFS rates, the immunophenotype was not identified as a risk factor.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The poor response and survival of patients who had PTCLs, compared with patients who had DLBCL, was caused by numerous initial risk factors. T\u2010cell phenotype itself did not appear to have a significant impact on either response or survival. Cancer 2007 \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22507","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T14:45:18Z","timestamp":1171982718000},"page":"1146-1151","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of peripheral T\u2010cell lymphomas and diffuse large B\u2010cell lymphoma"],"prefix":"10.1002","volume":"109","author":[{"given":"Naoto","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Hyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiya","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,2,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033"},{"key":"e_1_2_6_4_2","volume-title":"Tumours of Haematopoietic and Lymphoid Tissues: Pathology and Genetics. World Health Organization Classification of Tumours","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh409"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20531"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.45.1549"},{"key":"e_1_2_6_8_2","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10699"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V72.2.436.436","article-title":"The prognostic significance of the immunophenotype in diffuse large cell lymphomas: a comparative study of the T\u2010cell and B\u2010cell phenotype","volume":"72","author":"Lippman SM","year":"1988","journal-title":"Blood."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.6.725"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1426"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609045720"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.12.4514"},{"key":"e_1_2_6_17_2","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de' l'Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22507","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:21:04Z","timestamp":1760300464000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,20]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,3,15]]}},"alternative-id":["10.1002\/cncr.22507"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22507","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,20]]}}}